Hernández-Prat, Anna <br/><br/>
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.  [electronic resource] 

 -  Molecular cancer research : MCR  09 2019 
 - 1931-1944 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3125 
<br/><br/><label>Standard No.: </label>10.1158/1541-7786.MCR-18-0923  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Benzoxazoles--administration & dosage<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Mechanistic Target of Rapamycin Complex 1--antagonists & inhibitors<br/>Mechanistic Target of Rapamycin Complex 2--antagonists & inhibitors<br/>Mice<br/>Morpholines--administration & dosage<br/>Paclitaxel--administration & dosage<br/>Pyridines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Urinary Bladder Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays